The panel will decide whether to recommend the Moderna COVID-19 booster shot on Thursday. The Johnson & Johnson vaccine will be discussed on Friday.
Washington — The U.S. Food and Drug Administration Advisory Board will meet the first of two meetings this Thursday to recommend boost immunization of the COVID-19 vaccine from Moderna and Johnson & Johnson, and to secure another boost. Discuss if you can do it. Brand more than your first vaccine.
Currently, the Pfizer-BioNTech vaccine is the only vaccine in favor of the FDA, but Pfizer Shot boosters are still Americans over the age of 65, Americans with underlying health, or working. Only approved by certain Americans, such as front-line workers who are at an increased risk of being infected with COVID.
Both the Moderna and Johnson & Johnson vaccines are currently approved by the FDA for use in people over the age of 18, while the Pfizer vaccine is approved for Americans over the age of 12.
At the table on Thursday, the Moderna shot is the first. Moderna is asking the FDA to approve booster shots six months after the second dose, similar to Pfizer’s request. Johnson & Johnson Boosters will be discussed on Friday. They requested booster approval two months after the single-dose vaccine.
This week’s meeting is the first step in the approval process. Based on the advisory board’s recommendations, the FDA will decide whether to approve the booster. The Centers for Disease Control and Prevention then has the final say.
The FDA Panel endorsed Pfizer boosters for some groups on September 17th. Five days later, the FDA approved the shot, and CDC director Rochelle Walensky signed off on September 24th.
Another interesting debate expected during the Friday meeting is whether it is safe and effective for people to get booster shots of brands different from the original vaccine dose.
A preliminary study conducted by the National Institute of Infectious Diseases earlier this week found that mixing and matching booster and initial vaccine doses could be even more beneficial to those who received Johnson & Johnson injections. Was shown. The results showed that people who received the first J & J vaccine showed a higher immune response with different brand boosters than with additional Johnson & Johnson shots.
“It is important to evaluate information about the use of booster doses in different populations, as the available data reveal that protection against symptomatic COVID-19 in certain populations begins to diminish over time.” Said FDA’s Peter Marks in a press release.
Later this month, the same FDA Advisory Board will meet to discuss approval of the Pfizer vaccine for children ages 5-11.
FDA Advisory Board discusses Moderna, J & J COVID boosters
Source link FDA Advisory Board discusses Moderna, J & J COVID boosters